Search research articles
Contact Us
Filters
Showing results (71-80 of 148) with videos related to
Page
of 15
Sort By:
Geburtshilfe Und Frauenheilkunde
|
April 29, 2014
Participation in the SUCCESS-A Trial Improves Intensity and Quality of Care for Patients with Primary Breast Cancer
U Andergassen, N S Kasprowicz, P Hepp, et al.
Archives of Gynecology and Obstetrics
|
February 12, 2025
Influence of breast cancer on life satisfaction in the elderly patient
M Burgmann, K Hermelink, A Lotz, et al.
The International Journal of Biological Markers
|
April 14, 2000
Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer
A Prechtl, N Harbeck, C Thomssen, et al.
British Journal of Cancer
|
April 1, 2016
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study
W Janni, N Harbeck, B Rack, et al.
British Journal of Cancer
|
April 17, 1999
Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc
W Kuhn, B Schmalfeldt, U Reuning, et al.
Breast Cancer Research and Treatment
|
May 13, 2015
Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer
Christoph Scholz, U Andergassen, P Hepp, et al.
ESMO Open
|
March 19, 2025
Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial
N Harbeck, V Dieras, K A Gelmon, et al.
International Journal of Oncology
|
September 21, 2000
New ELISA for quantitation of human urokinase receptor (CD87) in cancer
M Kotzsch, T Luther, N Harbeck, et al.
Breast Cancer Research and Treatment
|
March 31, 2021
Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer
H Helbrich, M Braun, C Hanusch, et al.
Anticancer Research
|
March 2, 2005
Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer
B Werle, M Kotzsch, T T Lah, et al.
Page
of 15
Search research articles
Search
Showing results (71-80 of 148) with videos related to
Sort By:
Page
of 15
Geburtshilfe Und Frauenheilkunde
|
April 29, 2014
Participation in the SUCCESS-A Trial Improves Intensity and Quality of Care for Patients with Primary Breast Cancer
U Andergassen, N S Kasprowicz, P Hepp, et al.
Archives of Gynecology and Obstetrics
|
February 12, 2025
Influence of breast cancer on life satisfaction in the elderly patient
M Burgmann, K Hermelink, A Lotz, et al.
The International Journal of Biological Markers
|
April 14, 2000
Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer
A Prechtl, N Harbeck, C Thomssen, et al.
British Journal of Cancer
|
April 1, 2016
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study
W Janni, N Harbeck, B Rack, et al.
British Journal of Cancer
|
April 17, 1999
Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc
W Kuhn, B Schmalfeldt, U Reuning, et al.
Breast Cancer Research and Treatment
|
May 13, 2015
Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer
Christoph Scholz, U Andergassen, P Hepp, et al.
ESMO Open
|
March 19, 2025
Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial
N Harbeck, V Dieras, K A Gelmon, et al.
International Journal of Oncology
|
September 21, 2000
New ELISA for quantitation of human urokinase receptor (CD87) in cancer
M Kotzsch, T Luther, N Harbeck, et al.
Breast Cancer Research and Treatment
|
March 31, 2021
Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer
H Helbrich, M Braun, C Hanusch, et al.
Anticancer Research
|
March 2, 2005
Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer
B Werle, M Kotzsch, T T Lah, et al.
Page
of 15